AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26774179
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter)
Trial: 18319306
Drug: Metformin (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (425 mg/d for 2 yr, then 850 mg/d for 2 yr)
Trial: 12886210
Drug: No thermocycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thermocycling treatment
Trial: 10073863
Drug: High-density lipoprotein
RxNorm normalized name: Cholesterol in High-density lipoprotein (HDL) 2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density lipoprotein (HDL) raising treatment with nicotinic acid
Trial: 10073863
Drug: Low-density lipoprotein
RxNorm normalized name: Low-density lipoprotein receptor kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-density lipoprotein (LDL) lowering therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitor
Trial: 10073863
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy (beta-carotene and vitamins E and C)
Trial: 10073863
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy (warfarin)
Trial: 27031850
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with chemotherapy
Trial: 22078631
Drug: Physiological modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological modulators (PMs) with antioxidant action (MF Templar®)
Trial: 17890871
Drug: Continuous frusemide
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous frusemide infusion
Trial: 17890871
Drug: Regular intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intermittent intravenous boluses of frusemide
Trial: 9696954
Drug: Controlled-release levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal (30 min before ingestion)
Trial: 9696954
Drug: Controlled-release levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after fasting (2 hours after ingestion)
Trial: 9696954
Drug: Controlled-release levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal
Trial: 9696954
Drug: Controlled-release levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after fasting
Trial: 29629694
Drug: Gastric lavage
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric lavage with normal saline at 10 mL per kg body weight (n=350)
Trial: 23448313
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine prescription from clinician A
Trial: 23448313
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine prescription from clinician B
Trial: 23448313
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine prescription from clinician C
Trial: 16968585
Drug: NXY-059 (8-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 (8-h and 72-h intravenous infusions)
Trial: 16968585
Drug: Placebo (8-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8-h and 72-h intravenous infusions)
Trial: 2722729
Drug: Cefmetazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (3 doses of 1 g)
Trial: 2722729
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 doses of 2 g)
Trial: 23517585
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy for at least two months
Trial: 23517585
Drug: Peak vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak vascular response following breath hold tests in OSA patients before CPAP therapy
Trial: 15031595
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial infusion chemotherapy (TAI)
Trial: 11223117
Drug: Bromperidol (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromperidol (6, 12, or 18 mg/day for 3 weeks)
Trial: 11223117
Drug: Nemonapride (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonapride (18 mg/day for 3 weeks)
Trial: 8425670
Drug: Ponalrestat 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponalrestat 600 mg once daily
Trial: 31982096
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of Parent Management Training (PMT) and child Cognitive Behavioral Therapy (CBT)
Trial: 31982096
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of PMT and child CBT
Trial: 29265084
Drug: Noophen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noophen with standard therapy (n=33)
Trial: 29265084
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy only (Control group, n=20)
Trial: 21306285
Drug: Proactive multifactorial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive multifactorial risk factor intervention strategy using single‐pill amlodipine/atorvastatin (5/10, 10/10 mg)
Trial: 18769080
Drug: Midazolam 50
RxNorm normalized name: midazolam 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 50 microg/kg with normal saline 1 ml/kg
Trial: 18769080
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 1 ml/kg
Trial: 14614669
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin ointment, twice daily for 2 weeks
Trial: 10781652
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy with oral 17beta-estradiol or transdermal 17beta-estradiol, and oral norethisterone.
Trial: 26449959
Drug: Methylergonovine and
RxNorm normalized name: methylergonovine
DrugBank: Methylergometrine (DB00353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylergonovine and oxytocin infusion
Trial: 26449959
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion only
Trial: 16358163
Drug: Patient-Controlled Sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Sedation (PCS) with midazolam: loading dose 0.028 mg/kg, bolus dose 1 mg, lock-out period 5 min, basal infusion rate 0.
Trial: 16358163
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 1 microg/kg of fentanyl (i.v.) and 0.028 mg/kg of midazolam (i.v.).
Trial: 9564199
Drug: Adderall 5
RxNorm normalized name: Adderall 5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall 5 mg
Trial: 9564199
Drug: Adderall 15
RxNorm normalized name: Adderall 15mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall 15 mg
Trial: 9564199
Drug: Adderall 20
RxNorm normalized name: Adderall 20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall 20 mg
Trial: 7815676
Drug: Long-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain triglycerides (LCTs) infusion (0.07 g/kg.h‐1)
Trial: 7815676
Drug: Medium-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs) mixture infusion (50/50%, 0.07 g/kg.h‐1)
Trial: 7815676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (glucose infusion only)
Trial: 2651632
Drug: Cimetidine (30‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (30‐40 mg/kg/day)
Trial: 19125855
Drug: Amlodipine/atorvastatin (5/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/atorvastatin (5/20 mg) plus therapeutic lifestyle changes (TLC)
Trial: 11198157
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group with conventional analgesia (ketorolac I.V. 0.5 mg/kg/6 hours)
Trial: 9176747
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 day 1, etoposide 130 mg/m2 days 1‐3
Trial: 9176747
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2, vinblastine 6 mg/m2, mitomycin 10 mg/m2 day 1
Trial: 1548947
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prednisone and Vital HN (group III)
Trial: 24902959
Drug: Community medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community medicine distributors (CMDs)
Trial: 12470183
Drug: Rasagiline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 2 mg per day
Trial: 17393324
Drug: ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (8 mg bid)
Trial: 11254118
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination drug therapies (including DTIC plus interferon-alpha)
Trial: 11254118
Drug: DTIC-containing multi-drug
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC-containing multi-drug regimens
Trial: 11254118
Drug: Non-DTIC-containing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-DTIC-containing treatment programmes
Trial: 9883438
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (paraffin-impregnated gauze, Jelonet)
Trial: 2201224
Drug: Controlled-release dihydrocodeine
RxNorm normalized name: dihydrocodeine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release dihydrocodeine
Trial: 2619027
Drug: Antiemetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiemetic therapy
Trial: 28759396
Drug: 5-mL syringe
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mL syringe for 2-mL dose
Trial: 28759396
Drug: 10-mL syringe
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-mL syringe for 7.5-mL dose
Trial: 19851159
Drug: USG guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG guided injection (triamcinolone 40 mg)
Trial: 19851159
Drug: LMG guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMG guided injection (triamcinolone 40 mg)
Trial: 19851159
Drug: USG guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG guided injection
Trial: 19851159
Drug: LMG guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMG guided injection
Trial: 16720966
Drug: Function-centred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Function-centred treatment (FCT) group with Functional Capacity Evaluation (FCE) results available to physicians.
Trial: 16720966
Drug: Pain-centred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-centred treatment (PCT) group without FCE results available to physicians.
Trial: 14707315
Drug: Ropinirole 0.25‐4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole 0.25‐4.0 mg once daily
Trial: 11583826
Drug: ACE-inhibitors and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitors and steroids
Trial: 6360111
Drug: Orthokeratology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthokeratology treatment group
Trial: 31668907
Drug: Manual Circumlaryngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Circumlaryngeal Therapy (MCT)
Trial: 27082620
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) with 15 mL of 0.33% ropivacaine
Trial: 16948810
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection before pneumatic dilatation
Trial: 6828829
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment (1 Watt/cm2)
Trial: 6828829
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment in lidocaine blocked fibromyotic muscle
Trial: 6828829
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment in normal lidocaine pretreated muscle
Trial: 31964381
Drug: Intrafractional vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrafractional vaginal dilation using a tampon of a specific diameter during treatment.
Trial: 31964381
Drug: Standard (chemo)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (chemo) radiation with a total dose of 45-50.4 Gy to the pelvic and inguinal nodes with a boost to the anal canal up to 54-60 Gy.
Trial: 31964381
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of a tampon during treatment.
Trial: 28930830
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.3% ropivacaine plus 2 mL 1.0 μg/kg dexmedetomidine (group DR)
Trial: 28930830
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.3% ropivacaine plus 2 mL normal saline (group R)
Trial: 11006919
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of extra virgin olive oil per day
Trial: 11006919
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of refined olive oil with no simple phenols
Trial: 11006919
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of extra virgin olive oil (Postprandial trial)
Trial: 2938520
Drug: Midazolam-alfentanil combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-alfentanil combination
Trial: 27020439
Drug: Uninterrupted use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted use of novel oral anticoagulants (NOACs) (group I, n = 64)
Trial: 27020439
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of vitamin K antagonist (VKA) with INR between 2.0 and 3.0 (group III, n = 43)
Trial: 27020439
Drug: VKA discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA discontinuation bridged with low molecular weight heparin (group IV, n = 43)
Trial: 25190056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual care: STI testing, treatment, and counseling)
Trial: 21036834
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B with 500 mL of physiologic saline and 30 mL (60 meq/L) of KCl
Trial: 21036834
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B only (1 mg/kg/day for 20 days)
Trial: 18834340
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 100 microg
Trial: 18834340
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 200 microg
Trial: 16086715
Drug: Budesonide 6
RxNorm normalized name: budesonide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 6 mg
Trial: 11387857
Drug: Biofeedback‐assisted relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback‐assisted relaxation training (10 sessions of weekly training)
Trial: 9702851
Drug: Eprosartan 300
RxNorm normalized name: eprosartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 300 mg twice a day for 7 days
Trial: 9702851
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 7 days
Trial: 2574906
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with H2-receptor antagonists
Trial: 26003642
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection (100 mL once a day for 7 days)
Trial: 19298620
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in a proposed emergency treatment trial for SAH
Trial: 16520413
Drug: Optimal postinfarction
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal postinfarction therapy (Control)
Trial: 1630805
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment for chronic type B hepatitis
Trial: 1630805
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment for chronic type C hepatitis
Trial: 1630805
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment for hepatitis Delta infection
Trial: 8096880
Drug: Fenoterol 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 0.4 mg
Trial: 6368141
Drug: Fenoterol 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol 0.8 mg
Trial: 23833852
Drug: Ropivacaine 0.165%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.165% with fentanyl 2.0 micro g/ml
Trial: 23833852
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% with fentanyl 2.0 micro g/ml
Trial: 21092287
Drug: PEG‐IFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alpha‐2b (40‐kDa), single 180 micrograms dose, subcutaneously administered
Trial: 21092287
Drug: PEG‐IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alpha‐2a (reference), single 180 micrograms dose, subcutaneously administered
Trial: 21487851
Drug: Celsior solution
RxNorm normalized name: Fraxinus excelsior leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior solution (CS)
Trial: 10640263
Drug: pivampicillin plus
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivampicillin plus pivmecillinam (40 mg/kg/day and 50 mg/kg/day respectively)
Trial: 10640263
Drug: pivampicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivampicillin (50 mg/kg/day)
Trial: 3932049
Drug: Misoprostol 100
RxNorm normalized name: MISOPROSTOL 100MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 100 micrograms administered q.i.d. for up to four weeks